title: Acute myeloid/NK precursor cell leukemia with trisomy 4 and a novel point mutation in the extracellular domain of the G-CSF receptor in a patient with chronic idiopathic neutropenia.
abstract: Chronic idiopathic neutropenia (CIN) has been well recognized as a granulocytic disorder not associated with increased risk to malignant transformation. Four cases, however, of acute myeloid leukemia have been recently reported in patients with CIN. In the current paper, we report on a CIN patient who developed acute myeloid/natural killer (NK) precursor cell leukemia 11 years after diagnosis and 4 months after initiation of treatment with recombinant human granulocyte colony-stimulating factor (rhG-CSF). Leukemic cells had trisomy 4 as the sole cytogenetic abnormality and, also, a novel point mutation in the extracellular domain of the G-CSF receptor (G-CSFR) leading to truncated protein with a loss of 36 amino acids. There was no evidence that this receptor transmitted signals even in the presence of high doses of rhG-CSF in the cultures. We consider that CIN may be a preleukemic condition, at least in a subset of patients, and that rhG-CSF administration is unlikely to be involved in the leukemic transformation in this patient, although such a possibility could not be completely ruled out.
authors.affiliation: Department of Hematology of the University of Crete School of Medicine, University Hospital of Heraklion, P.O. Box 1352, Heraklion, Crete, Greece. epapadak@med.uoc.gr
authors.forename: H A
authors.initials: HA
authors.lastname: Papadaki
authors.forename: T
authors.initials: T
authors.lastname: Kosteas
authors.forename: C
authors.initials: C
authors.lastname: Gemetzi
authors.forename: A
authors.initials: A
authors.lastname: Damianaki
authors.forename: N P
authors.initials: NP
authors.lastname: Anagnou
authors.forename: G D
authors.initials: GD
authors.lastname: Eliopoulos
mesh_terms: D001483:Base Sequence; D002894:Chromosomes, Human, Pair 4 / Q000235:genetics*; D005110:Extracellular Space / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D007621:Karyotyping; D007694:Killer Cells, Natural / Q000473:pathology*; D007951:Leukemia, Myeloid / Q000097:blood / Q000209:etiology / Q000235:genetics* / Q000473:pathology; D008875:Middle Aged; D023461:Myeloid Progenitor Cells / Q000473:pathology*; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D017354:Point Mutation; D017434:Protein Structure, Tertiary; D012333:RNA, Messenger / Q000235:genetics; D016188:Receptors, Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000737:chemistry / Q000235:genetics*; D011994:Recombinant Proteins / Q000008:administration & dosage; D014314:Trisomy
chemical_list: D012333:RNA, Messenger; D016188:Receptors, Granulocyte Colony-Stimulating Factor; D011994:Recombinant Proteins